Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

TGF alpha L3-SEB fusion protein as an anticancer against ovarian cancer

Sun Mar 26 18:41:42 2023

(2020) TGF alpha L3-SEB fusion protein as an anticancer against ovarian cancer. European Journal of Pharmacology. p. 8. ISSN 0014-2999

Full text not available from this repository.

Official URL: http://apps.webofknowledge.com/InboundService.do?F...

Abstract

TGF alpha L3-SEB is a new synthetic fusion protein produced by the combination of the third loop of transforming growth factor with staphylococcal enterotoxin type B. In the current study, the anti-tumor effects of TGF alpha L3-SEB were evaluated against SKOV3 cells, which highly expressed the epidermal growth factor receptor (EGFR). Our findings showed that incubation of SKOV3 cells with 75, 100 and 150 mu g/ml of TGF alpha L3-SEB significantly reduces the proliferation rate in a concentration-dependent manner (P < 0.05) and its IC50 value was 110 mu g/ml. Caspase-3 activity was increased from 100 for control cells to 109, 144, and 169 for 75, 100 and 150 mu g/ml of TGF alpha L3-SEB treatment, respectively. Caspase-9 activity and bax/bcl-2 ratio were also confirmed the apoptosis induction ability of TGF alpha L3-SEB (P < 0.001). Flow cytometry examination also showed that apoptosis was induced and the number of apoptotic cells was increased from 8.2 in un-treated cells to 20.9, 50, and 90 in response to 75, 100 and 150 mu g/ml of TGF alpha L3-SEB fusion protein in a concentration-dependent manner (P < 0.05). The mRNA expression level of VEGF was also reduced to 0.89, 0.69, and 0.60, respectively in response to 75, 100 and 150 mu g/ml of TGF alpha L3-SEB fusion protein exposure, respectively (P < 0.5). In summary, the findings of our study uncovered that TGF alpha L3-SEB fusion protein induced apoptosis and reduced angiogenesis in SKOV3 ovarian cancer cells in a concentration-dependent manner. This protein has the potential to act against EGFR expressing malignant cells to serve as a pro-apoptotic and angiogenesis blocker agents; however, further studies are needed to confirm its ability.

Item Type: Article
Creators:
CreatorsEmail
Maleki, F.UNSPECIFIED
Sadeghifard, N.UNSPECIFIED
Sedighian, H.UNSPECIFIED
Bakhtiyari, S.UNSPECIFIED
Hosseini, H. M.UNSPECIFIED
Fooladi, A. A. I.UNSPECIFIED
Keywords: Apoptosis Necrosis EGFR Ovarian cancer Angiogenesis TGF alpha L3-SEB fusion protein epidermal-growth-factor tyrosine kinase inhibitors regulates vegf expression in-vitro evaluation enterotoxin type-b antitumor-activity targeted delivery crystal-structure cells receptor Pharmacology & Pharmacy
Divisions:
Page Range: p. 8
Journal or Publication Title: European Journal of Pharmacology
Journal Index: ISI
Volume: 870
Identification Number: https://doi.org/10.1016/j.ejphar.2020.172919
ISSN: 0014-2999
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/2609

Actions (login required)

View Item View Item